This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (COMBAT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by In-Jae, Oh, MD, Chonnam National University Hospital.
Recruitment status was:  Recruiting
Chong Kun Dang Pharmaceutical
Information provided by (Responsible Party):
In-Jae, Oh, MD, Chonnam National University Hospital Identifier:
First received: January 21, 2009
Last updated: January 9, 2012
Last verified: January 2012

Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer.

Primary endpoints

  • to assess Response Rate

Secondary endpoints

  • to assess Overall response duration, Time to progression, Overall survival

Condition Intervention Phase
Carcinoma, Small Cell Drug: Belotecan/Cisplatin Drug: Etoposide/Cisplatin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by In-Jae, Oh, MD, Chonnam National University Hospital:

Primary Outcome Measures:
  • To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer [ Time Frame: two years ]

Secondary Outcome Measures:
  • to assess the overall response duration [ Time Frame: two years ]
  • To assess the time to progression [ Time Frame: two years ]
  • to assess the overall survival [ Time Frame: two years ]

Estimated Enrollment: 150
Study Start Date: January 2009
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Belotecan Drug: Belotecan/Cisplatin
Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.
Active Comparator: Etoposide Drug: Etoposide/Cisplatin
Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.


Ages Eligible for Study:   19 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG Performance status 0~2(those with performance status 2 must have been stable with no deterioration over the previous 2 weeks)
  • Histologically or cytologically confirmed small cell lung cancer Patient without chemotherapy and radiotherapy
  • Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site
  • Life expectancy of at least 3 months
  • Provision of written informed consent

Exclusion Criteria:

  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease
  • Serum bilirubin greater than 3 times the upper limit of reference range(ULRR)
  • Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT)greater than 2.5 times ULN if no demonstrable liver metastases (or > 5 times in presence of liver metastases)
  • Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
  • Pregnancy or breast-feeding women(women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
  • Evidence of brain metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826644

Contact: In-Jae Oh, M.D.,Ph.D. 82-61-379-7617
Contact: Kyu-Sik Kim, M.D.,Ph.D. 82-61-379-7615

Korea, Republic of
Chonnam National University Hwasun Hospital Recruiting
Hwasun-gun, Jeonnam, Korea, Republic of
Contact: In-Jae Oh, M.D.,Ph.D.    82-61-379-7617   
Sponsors and Collaborators
Chonnam National University Hospital
Chong Kun Dang Pharmaceutical
Principal Investigator: In-Jae Oh, M.D.,Ph.D. Chonnam National University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: In-Jae, Oh, MD, Assistant Professor, Chonnam National University Hospital Identifier: NCT00826644     History of Changes
Other Study ID Numbers: CSCLC-0810
Study First Received: January 21, 2009
Last Updated: January 9, 2012

Keywords provided by In-Jae, Oh, MD, Chonnam National University Hospital:
Small cell lung cancer
Response rate

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Small Cell
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors processed this record on September 21, 2017